Fenofibrate-d6 structure
|
Common Name | Fenofibrate-d6 | ||
---|---|---|---|---|
CAS Number | 1092484-56-4 | Molecular Weight | 366.868 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 469.8±35.0 °C at 760 mmHg | |
Molecular Formula | C20H15ClD6O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 165.4±24.9 °C |
Use of Fenofibrate-d6Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively. |
Name | propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-3,3,3-trideuterio-2-(trideuteriomethyl)propanoate |
---|---|
Synonym | More Synonyms |
Description | Fenofibrate-d6 is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively. |
---|---|
Related Catalog | |
In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 469.8±35.0 °C at 760 mmHg |
Molecular Formula | C20H15ClD6O4 |
Molecular Weight | 366.868 |
Flash Point | 165.4±24.9 °C |
Exact Mass | 366.150482 |
PSA | 52.60000 |
LogP | 4.80 |
Vapour Pressure | 0.0±1.2 mmHg at 25°C |
Index of Refraction | 1.547 |
Lipirex-d6 |
Nolipax-d6 |
Isopropyl 2-[4-(4-chlorobenzoyl)phenoxy]-2-(H)methyl(H)propanoate |
Lipofene-d6 |
Lipsin-d6 |
Lipantil-d6 |
Lipanthyl-d6 |
Propanoic-3,3,3-d acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-(methyl-d)-, 1-methylethyl ester |
Fenofibrate-d6 |
Liposit-d6 |
MeltDose-d6 |
Lipoclar-d6 |